New Study Shows MenaQ7® Vitamin K2 plus Vitamin D  Slows Progression of Arterial Calcification

OSLO, NORWAY -- In a pioneering, just-completed prospective randomized human clincal trail in patients with chronic renal disease, the cardiovascular effects of oral administration of vitamin K2 (MenaQ7® brand) plus vitamin D or vitamin D alone were evaluated. In this six-month study, the progression of coronary artery calcification index (CAC) and common carotid intima media thickness (CCA-IMT) – both markers of calcium deposits in arteries detected with computerized tomography -- showed a slower progression of the calcification in the vitamin K2/vitamin D group than detected in the vitamin D-alone group of patients.

Prof. Michal Nowicki, the principal investigator, and Ilona Kurnatowska, MD, PhD, a lead author on the study both from Department of Nephrology, Hypertension and Kidney Transplantation, Medical University, Lodz, Poland, noted, "In this study, the K2 and D protected against cardiovascular calcification, while the D group alone did not. Clearly, this has positive implications for human health."  The clinical data was presented at 50th ERA-EDTA Congress, May 18-21, 2013, Istanbul, Turkey, and published by Oxford University press in Nephrology Dialysis Transplantation.

Hogne Vik, CEO in NattoPharma ASA, Oslo, Norway, the manufacturer of MenaQ7, the vitamin K2 used in the study, stated that, “to the best of my knowledge this is the first clinical evaluation showing that progression of arterial calcification can be prevented with supplemental vitamin K2.”

The study abstract titled, “The effect of vitamin K2 supplementation on atherosclerosis and vascular calcification makers in non-dialyzed patients in chronic kidney disease stage 3-5,”  was published in an abstract form by the Oxford University Press in Nephrology Dialysis Transplantation.      

About NattoPharma and MenaQ7®

As a biotechnology-based nutraceutical company, NattoPharma is the worldwide innovator of Vitamin K2 menaquinone-7. Its brand MenaQ7® is supported by a global IPR portfolio and research substantiating clear efficacy for bone and cardiovascular health. NattoPharma has since 2007 been in an exclusive research and development collaboration with VitaK, University in Maastricht, The Netherlands, working to substantiate the health benefits of natural vitamin K2.

For more information, please contact: 

Eric Andersson,
Senior VP Global Sales & Marketing,
+1 732 725 51 91 / eric@nattopharma.com

Hogne Vik, MD, PhD,
CEO
+47 975 35 326 / hogne.vik@nattopharma.com

Tags: